Polymer-ritonavir derivate nanomedicine with pH-sensitive activation possesses potent anti-tumor activity in vivo via inhibition of proteasome and STAT3 signaling-Reference-Cited by-同舟云学术

Polymer-ritonavir derivate nanomedicine with pH-sensitive activation possesses potent anti-tumor activity in vivo via inhibition of proteasome and STAT3 signaling

Published:2021-04 Issue: Volume:332 Page:563-580
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Sivák Ladislav,Šubr Vladimír,Kovářová Jiřina,Dvořáková Barbora,Šírová Milada,Říhová Blanka,Randárová Eva,Kraus Michal,Tomala Jakub,Studenovský Martin,Vondráčková Michaela,Sedláček Radislav,Makovický Petr,Fučíková Jitka,Vošáhlíková Šárka,Špíšek Radek,Kostka Libor,Etrych Tomáš,Kovář Marek

Funder

Ministerstvo Školství, Mládeže a Tělovýchovy

Grantová Agentura České Republiky

European Regional Development Fund

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference57 articles.

1. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy;Perez-Herrero;Eur. J. Pharma. Biopharm.,2015

2. Finding new tricks for old drugs: an efficient route for public-sector drug discovery;O’Connor;Nat. Rev. Drug Discov.,2005

3. Drug repositioning: identifying and developing new uses for existing drugs;Ashburn;Nat. Rev. Drug Discov.,2004